Among all the drugs used in T2DM therapy, one seems to be more promising and shows evident benefits in patients with NAFLD: sodium-glucose cotransporter (SGLT2) inhibitors. The gene discussed is SLC5A2; the disease is metabolic dysfunction-associated steatotic liver disease.